Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence

Current Medical Research and Opinion
Linda CardozoYan D Zhao

Abstract

To evaluate short- and long-term safety and efficacy of duloxetine in women with predominant stress urinary incontinence (SUI). The study was a 6-week, double-blind, randomised, parallel, placebo-controlled study followed by an uncontrolled open-label extension (OLE) run in 342 study centres in 16 European countries. Women with predominant SUI were randomly assigned to placebo (n = 1380) or duloxetine 40 mg twice daily (n = 1378) for 6 weeks. Completers of the acute phase were enrolled in the OLE, which had a minimum duration of 6 weeks and ended, based on the approval status of duloxetine in the participating country. The primary outcome measure was the change in incontinence episode frequency (IEF) over 6 weeks. Secondary outcome measures were the long-term maintenance of effect on IEF and Patient Global Impression of Improvement (PGI-I), the short- and long-term impact on quality of life using the King's Health Questionnaire (KHQ), and the long-term safety of duloxetine. After 6 weeks, the decrease in weekly IEF was significantly greater with duloxetine treatment compared to placebo (-50.0 vs. -29.9%; p < 0.001). The percentage of responders (defined as > or =50% decrease in IEF) was significantly higher with duloxetine trea...Continue Reading

References

May 1, 1996·British Journal of Pharmacology·H Danuser, K B Thor
Jan 9, 1998·British Journal of Obstetrics and Gynaecology·C J KelleherS Salvatore
Feb 22, 2002·Neurourology and Urodynamics·Paul AbramsUNKNOWN Standardisation Sub-committee of the International Continence Society
Jul 13, 2002·American Journal of Obstetrics and Gynecology·Peggy A NortonUNKNOWN Duloxetine Urinary Incontinence Study Group
Jul 16, 2003·American Journal of Obstetrics and Gynecology·Ilker Yalcin, Richard C Bump
Sep 23, 2003·The Journal of Urology·Roger R DmochowskiUNKNOWN Duloxetine Urinary Incontinence Study Group
Nov 25, 2003·American Journal of Obstetrics and Gynecology·Nancy H FultzRichard C Bump
Feb 7, 2004·BJU International·R J MillardUNKNOWN Duloxetine UI Study Group
Feb 14, 2004·BJOG : an International Journal of Obstetrics and Gynaecology·Philip van KerrebroeckUNKNOWN Duloxetine Urinary Incontinence Study Group
Sep 2, 2004·Obstetrics and Gynecology·Linda CardozoRichard C Bump
Apr 12, 2005·The Journal of Urology·Gamal M GhoniemUNKNOWN Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group
May 3, 2005·Obstetrics and Gynecology·Kari BøIngrid Nygaard
Sep 29, 2005·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Daniel J HurleySimin K Baygani
Oct 4, 2005·Obstetrics and Gynecology·Alfred E BentUNKNOWN Duloxetine Mixed Urinary Incontinence Study Group
Mar 15, 2006·BJOG : an International Journal of Obstetrics and Gynaecology·R M Freeman
Mar 15, 2006·BJOG : an International Journal of Obstetrics and Gynaecology·M OelkeM C Michel
Dec 13, 2006·International Urogynecology Journal and Pelvic Floor Dysfunction·David Castro-DiazUNKNOWN Duloxetine Dose Escalation Study Group
Nov 17, 2007·Diseases of the Colon and Rectum·Nikki CotterillJenny L Donovan
Apr 22, 2008·BJU International·Richard C BumpWei Chen
May 16, 2009·Current Opinion in Urology·Ian Milsom

❮ Previous
Next ❯

Citations

Mar 19, 2013·International Urology and Nephrology·Jinhong LiPing Han
Mar 8, 2014·International Urogynecology Journal·Nadine Schwertner-TiepelmannRalf Tunn
Jul 6, 2014·Gynécologie, obstétrique & fertilité·R LousquyJ-F Hermieux
Oct 8, 2014·Current Urology Reports·Eugene W Lee, Kathleen C Kobashi
Sep 27, 2014·Life Sciences·Kimio SugayaHideyuki Yamamoto
Mar 15, 2012·Neurourology and Urodynamics·E CortesC Kelleher
May 8, 2019·Journal of General Internal Medicine·Ethan M BalkPeter C Jeppson
May 31, 2019·International Journal of Urology : Official Journal of the Japanese Urological Association·Tomohiro UedaNaoki Yoshimura
Nov 10, 2017·Acta Physiologica·K-E Andersson
Nov 17, 2020·Frontiers in Psychiatry·Daniela Rodrigues-AmorimTania Rivera-Baltanás
Mar 18, 2020·Journal of Clinical Anesthesia·Getúlio Rodrigues de Oliveira FilhoHeloísa de Cássia Dos Santos

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.